The efficacy and safety of Tocilizumab in adults with refractory systemic onset JIA
Pediatric Rheumatology volume 9, Article number: P137 (2011)
Systemic-onset JIA (so-JIA) is often persisting into adulthood and can be refractory to treatment including biologicals. We report on efficacy and safety of Tocilizumab in adults with persistent active so-JIA in a retrospective single center descriptive cohort study.
Patients and methods
Disease activity scores (DAS-CRP), ESR and CRP were measured just before and at 1- 6- and 12 months of Tocilizumab treatment in all adults with refractory so-JIA at our University Hospital. Adverse events were recorded.
Eight patients (5 women, 3 men) with a median age of 27,5yr and median disease duration of 16 yr were treated. All previously failed Methotrexate, other classical DMARD’s, 7/8 also failed on one or more biologicals (mostly TNF blockers, Anakinra in 1). Median HAQ before starting Tocilizumab was 1.25 (0.75-2.13). Tocilizumab dose was 8mg/kg/month, except for 1 patient receiving 6mg/kg/2 weeks. The median DAS-CRP decreased from 5,10(1.6-5.3) (n=6) at start to 2,25(1.3-2.9) (n=6) after six months (p=0,046). At 12 months, median DAS-CRP was 1,9(1.5-6.1)(n=3). Median ESR/CRP decreased from 35(15-87)(n=6)/69,2(9.1-292.6)mg/l(n=8) at start to
2(1-7)/1,2(0.6-1.4)mg/l(n=7) at six months (p=0,028/0,018). At 1 year median ESR/CRP were 3,5(1-13)(n=4)/0,6(0.6-23.1)mg/l(n=5). A decrease/complete stop of steroids was observed in 6 patients. Atypical rash was seen in one patient, EBV-induced MAS occurred in 1 patient after 7 yrs of Tocilizumab.
Our report on young adults with persistingly active so-JIA treated with Tocilizumab shows a fast, steep and persistent decrease in disease activity up to at least 1 year, demonstrating the efficacy of IL6-receptor antagonism also in patients with long-standing refractory so-JIA.
About this article
Cite this article
Deslypere, G., Wouters, C., Joly, J. et al. The efficacy and safety of Tocilizumab in adults with refractory systemic onset JIA. Pediatr Rheumatol 9 (Suppl 1), P137 (2011). https://doi.org/10.1186/1546-0096-9-S1-P137